The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Anemia And Other Blood Disorder Drugs Market Expected To Scale Between 2026 And 2030?
The anemia and other blood disorder drugs market size has demonstrated significant growth in recent years. It is anticipated to expand from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This market’s historical expansion can be linked to factors including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the reliance on blood transfusions, the long-standing use of ESAs, and established hematology treatment protocols.
The market for drugs addressing anemia and other blood disorders is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a value of $16.88 billion, demonstrating a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by several factors, including the greater adoption of gene therapy, a growing elderly demographic, heightened public awareness of blood conditions, the proliferation of specialized hematology clinics, and more effective diagnostic procedures. Key developments expected during this period encompass an escalating incidence of chronic blood disorders, a greater reliance on injectable treatments, the broadening application of gene therapy for uncommon anemias, an enhanced emphasis on customized hematology solutions, and better availability of crucial blood disorder medications.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp
What Significant Factors Are Influencing The Anemia And Other Blood Disorder Drugs Market Expansion?
The increasing need for personalized medicine is anticipated to boost the expansion of the anemia and other blood disorder drugs market going forward. Personalized medicine is a healthcare strategy that leverages an individual’s genetic profile to direct decisions regarding prevention, diagnosis, and treatment. The escalating desire for personalized medicine stems from its capability to deliver more efficacious, targeted therapies, which leads to improved patient outcomes and long-term health. The anemia and other blood disorder drugs market supports individualized care by enabling tailored treatment plans that address the unique genetic or molecular characteristics of blood disorders. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults report feeling more anxious than they did the year before, an increase from 37% in 2023 and 32% in 2022. Consequently, the rising demand for personalized medicine is propelling the growth of the anemia and other blood disorder drugs market.
How Is Segmentation Applied In The Anemia And Other Blood Disorder Drugs Market Segment Analysis?
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)
What Trends Are Affecting The Growth Of The Anemia And Other Blood Disorder Drugs Market?
Major companies operating within the anemia and other blood disorder drugs market are prioritizing the introduction of new medications to enhance therapeutic results, broaden available treatments, and solidify their market standing. These novel medications represent innovative pharmaceutical solutions that offer fresh mechanisms of action, greater effectiveness, or enhanced safety profiles compared to current treatments, addressing critical needs in conditions like anemia and myelodysplastic syndromes. For example, in August 2023, the US-based pharmaceutical firm Bristol-Myers Squibb Company obtained FDA approval for Reblozyl. This drug is now approved as a first-line therapy for anemia in adults suffering from lower-risk myelodysplastic syndromes, marking it as the initial treatment to demonstrate superior performance over an erythropoiesis-stimulating agent in this particular context. This was supported by data from the Phase 3 COMMANDS trial, which indicated that almost twice as many patients treated with Reblozyl achieved at least 12 weeks of transfusion independence along with concurrent hemoglobin improvement, in contrast to those receiving Epoetin alfa.
Who Are The Companies Participating In The Anemia And Other Blood Disorder Drugs Market Environment?
Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.
Get The Full Anemia And Other Blood Disorder Drugs Market Report:
Which Region Accounts For The Largest Portion Of The Anemia And Other Blood Disorder Drugs Market?
North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Anemia And Other Blood Disorder Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company
Anemia And Other Blood Disorder Drugs Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Hematology Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model